Dr Michael Fahey
Honorary (Fellow)
The Sir Peter MacCallum Department of Oncology
63 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Radiotherapy dose–response of mycosis fungoides with large cell transformation
DOI: 10.1016/j.radonc.2025.1112922025
Journal article
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience
DOI: 10.1007/s00259-025-07235-w2025
Journal article
Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
DOI: 10.2967/jnumed.124.2692522025
Journal article
Neoadjuvant Chemoradiotherapy in Locally Advanced and Locally Recurrent Colon Cancer
DOI: 10.1016/j.clon.2024.1036922025
Journal article
Speech, Language and Non-verbal Communication in CLN2 and CLN3 Batten Disease
DOI: 10.1002/jimd.128382024
Journal article
Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma
DOI: 10.1016/j.oraloncology.2024.1070322024
Journal article
Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer
DOI: 10.1016/j.euo.2023.11.008
RECENT SCHOLARLY WORKS
2023
Journal article
Reviewing the risk of breast cancer recurrence following breast reconstruction
DOI: 10.1111/ans.185202023
Journal article
Preoperative radiotherapy for select T4 primary and locally recurrent colon cancers: Experience from an Australian quaternary centre.
DOI: 10.1200/jco.2023.41.16_suppl.e156562023
Conference Proceedings
LuCAB: A phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
DOI: 10.1200/jco.2023.41.6_suppl.tps278